Microbio has entered into a distributor agreement with Advisains to bring its innovative test, InfectID™-BSI, to healthcare providers in Indonesia. This partnership aims to enhance access to advanced diagnostics, enabling faster and more accurate detection of bloodstream infections across the region.
InfectID™-BSI is a groundbreaking molecular diagnostic test that identifies 26 sepsis-associated pathogens, enabling clinicians to administer targeted treatment in less than three hours. The assay works by targeting the pathogen’s DNA ‘fingerprint.’ Utilizing melt curve technology, InfectID™-BSI rapidly identifies sepsis-causing pathogens directly from blood samples. Without the need for enrichment or culture, this CE-marked product offers a powerful tool to improve patient outcomes through quicker and more accurate treatment, addressing sepsis, which contributes to millions of deaths globally each year.
Microbio is committed to improving patient outcomes through advanced diagnostic technologies, and this partnership marks a significant step in expanding access to InfectID™-BSI across Indonesia.
“By partnering with Advisains, we are excited to extend our reach into Indonesia, ensuring that healthcare providers in the region have access to InfectID™-BSI, a vital tool in the fight against sepsis. This collaboration marks an important step in our mission to improve patient outcomes through faster, more accurate pathogen identification” said Jeff Bryant, Distribution Manager APAC at Microbio.
“Microbio’s InfectID™-BSI technology provides the ability to analyze sepsis-causing pathogens more quickly (within 3 hours) and accurately with a genomic-based approach. Conventional methods often take a long time (more than 5 days) and are not always able to comprehensively detect sepsis-causing pathogens, making it difficult to determine the right therapy. Fast and accurate diagnosis not only saves lives but also reduces the financial burden on the health system. Therefore, this collaboration can be a game changer in overcoming the challenges of sepsis diagnosis to achieve national productivity towards Indonesia Emas 2045, starting from technical aspects, clinical implementation, to its potential impact in improving patient treatment outcomes.”, said Mr. Rifan Ahmad B.Sc., MBA, Director at Advisains.
Advisains, a healthcare solutions provider in Indonesia, is known for its extensive experience in the distribution of medical and diagnostic products. Their market expertise and robust network position them as an ideal partner for Microbio as it expands its presence in Asia.